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Purpose: Overuse of antibiotics is of concern, but may differ between European
countries. This study compares outpatient use of oral antibiotics between Germany
(DE) and the Netherlands (NL).
Methods: For DE, we used the DAPI database with information on dispensings at
the expense of the Statutory Health Insurance Funds from > 80% of community phar-
macies. For NL, data were obtained from the Dutch Foundation for Pharmaceutical
Statistics. Use of oral antibiotics was estimated as defined daily doses per 1000 inhab-
itants per day (DID), except for age comparisons as packages per 1000 inhabitants
annually. National time trends were assessed with linear regression, stratified for
the major antibiotic classes, and individual substances.
Results: From 2012 to 2016, outpatient antibiotic use was lower in NL than in DE
(9.64 vs 14.14 DID in 2016) and non‐significantly decreased slightly over time in both
countries. In DE, dispensings of oral antibiotics to children were higher compared with
NL for the age groups 2 to 5 (2.0‐fold in 2016) and 6 to 14 years (2.7‐fold in 2016).
Use of cephalosporins was very low in NL (0.02 DID in 2016), but the second most
frequently dispensed class in DE (2.95 DID in 2016).
Conclusion: From 2012 to 2016, outpatient use of oral antibiotics was lower in NL
than in DE. Differences were primarily observed in the age groups 2 to 5 and 6 to
14 years, although the recommendations of evidence‐based guidelines in both
countries were in agreement.
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The use of systemic antibiotics is subject to continuous surveillance
to understand antibiotic resistance development.1,2 This problem is
increasing and threatens the possibilities to treat common infection- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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KEY POINTS
• From 2012 to 2016, outpatient use of oral antibiotics
was lower in the Netherlands (NL) than in Germany
(DE) (9.64 DID vs 14.14 DID in 2016)
• Outpatient use of oral antibiotics non‐significantly
decreased slightly over time in both countries
• In DE, use of oral antibiotics in children was higher
compared with NL for the age groups 2 to 5 years
(2.0‐fold in 2016) and 6 to 14 years (2.7‐fold in 2016)
• Use of cephalosporins was very low in NL (0.02 DID in
2016) but the second most frequently dispensed class
of antibiotics in DE (2.95 DID in 2016)
GRADL ET AL. 1345diseases effectively.3 Thus, restrained use of antimicrobial medicines is
urgently advocated worldwide. The focus of improvement programs in
human medicine should be on outpatient prescribing of antibiotics
since during recent years, 85% to 95% of antibiotics have been
dispensed in the community in many countries worldwide.1,4
Numerous studies have quantified the overall use of systemic
antibiotics and elucidated specific antibiotic groups or substances in
European countries5 and use in different age groups.6-10 Within the
European Union, Germany (DE) and the Netherlands (NL) belong to
countries with a low antibiotic consumption.2 Both countries are
culturally comparable, in direct geographical neighborhood, and with
highly developed health care systems. However, antibiotic consump-
tion was substantially higher in DE during recent years compared with
NL.1,11,12 National preferences for types of antibiotics prescribed in
both countries, with the exception of penicillins as the antibiotic drug
class mostly prescribed, differed strongly between 2004 and 2015.
Most strikingly, cephalosporins were hardly used at all in NL whereas
their use has increased in DE.13,14 In DE, most patients who received
an antibiotic in ambulatory care in 2008 were diagnosed with respira-
tory tract (RTI) or genitourinary tract infections whereas in NL other
diagnoses were more frequent.13 The application of broad spectrum
agents for viral self‐limiting infections is of concern in DE, especially
in children and adolescents.8 In‐depth and contemporary studies,
however, are lacking, which may help to understand the reasons for
the differences for outpatient oral antibiotics dispensings in both
countries, eg, by looking at national guideline recommendations.
The goal of our study was, therefore, to compare directly the outpa-
tient use of oral antibiotics in DE and NL during the 5‐year period 2012
to 2016 and by age groups, antibiotic classes, and individual drugs in
particular. We further aimed at comparing actual guideline recommen-
dations for the two countries for RTI and urinary tract infections (UTI).
Since in DE frequent prescribing of clindamycin by dentists had been
observed,15-19 another focus of the study was dispensing of clindamycin
by dentists and the guidelines for odontogenic infections in DE.2 | METHODS
2.1 | Study design
A longitudinal drug utilization study20 for oral antibiotic use during the
years 2012 and 2016 was performed.2.2 | Data sources
In DE, information was available from the DAPI database, which con-
tains anonymous claims data of drugs prescribed and subsequently dis-
pensed at community pharmacies at the expense of the Statutory
Health Insurance (SHI) Funds. Nearly 87% of DE's population is insured
by the SHI system.21,22 The database covers all claims data from a rep-
resentative sample of more than 80% of the community pharmacies
throughout all regions. Dispensing data were linked to the ABDA data-
base containing information about the (brand) name, composition,
active ingredient, strength, package size, dosage form, and route of
administration of German medicinal products.23 Prescriptions by den-
tists could be identified by a specific code on the prescriptions.Prescriptions for privately insured patients and payed out‐of‐pockets
are not available in the DAPI database. Data on indication, treatment
duration, or dosages as well as data on individual patients including
gender are also not available, except for year of birth.
In NL, data were available from the Dutch Foundation for
Pharmaceutical Statistics (SFK) that collects dispensing data for drugs
prescribed from nearly 95% of all community pharmacies.24 All prescrip-
tions are registered for the concerning patient in the computer system
of the pharmacy. This registration is mandatory in NL to achieve a com-
plete file on all patient's medication in use, regardless of the insurance
status. Besides, all inhabitants are covered by a mandatory health insur-
ance system. These data provide detailed information on the drugs pre-
scribed, including the codes from the Anatomical Therapeutic Chemical
(ATC) classification system of the WHO,25 and the amount dispensed.
Thus, information on (brand) name, composition, active ingredient,
strength, package size, dosage form, and route of administration for
the dispensed antibiotics was available in the database of the SFK for
each individual antibiotic product on patient level. In the SFK, patients
are coded by an anonymous number from the computer system of
the local pharmacy. The only information further available is on patient's
gender and year of birth. Detailed information about the specialty of
the prescriber and the reason for prescribing is not available.
In both countries, oral antibiotics are prescription‐only and reim-
bursed by health insurance funds. In DE, data were extrapolated by
regional factors based on 80% to 100% of all community pharmacies,
and thus 100% of the SHI insured population. In NL, data were
extrapolated from 95% available to 100% of the community pharmacies,
and thus 100% of the total population. To enhance comparability, in NL,
the extrapolated data were related to the total population in the NL,
whereas in DE the extrapolated data were related to the SHI insured
population.2.3 | Measurement of antibiotic use
Systemic antibiotics, ATC Code J01,26 were analyzed on substance level
for orally administered antibiotics (ATC 5th level codes). For achieving
comparability between DE and NL, antibiotic use was estimated by
defined daily doses26 per 1000 inhabitants per day (DID). For DE, all
1346 GRADL ET AL.persons insured by the SHI system were used as a reference. These
numbers were obtained from the Federal Ministry of Health21 except
for children under 15 years of age. For the analysis of age groups (0‐
1, 2‐5, 6‐14, and ≥15 years of age), detailed numbers of SHI insured
children were needed. To estimate those, overall numbers of children
in DE for the years under investigation were obtained from the Federal
Statistical Office.22 An estimate for the number of subjects insured by
SHI was calculated subsequently as follows: The proportion of SHI
insured children in the age group 0 to 14 within the corresponding year
was multiplied by the total number of children in DE in the age groups 0
to 1, 2 to 5, and 6 to 14. For NL, overall population numbers retrieved
from the Central Agency of Statistics27 were used as a reference.
For the analysis by age group, the year of birth was available on
prescription level. Thus, during a year, a person contributed data to a
corresponding age group based on his or her age on 31 December.
In the sub‐analysis that focused on dispensings to children, antibiotic
use was defined as annual package numbers per 1000 inhabitants,
assuming one package as therapy unit. Defined daily doses could not
be used here as these are based on the average dosage for adults
and do not take into account age‐based and weight‐based dosing in
children of different age groups.282.4 | Statistical analysis
Comparison of oral antibiotic drug use between DE and NL was achieved
by the assessment of DIDs. DIDs dispensed in DE and NL were calcu-
lated in total, for the different major antibiotic classes (penicillins, cepha-
losporins, tetracyclines, quinolones, macrolides, lincosamides, and others
comprising sulfonamides/trimethoprim, aminoglycosides, glycopeptides,
fosfomycin, and nitrofuran derivatives) and for different individual sub-
stances. Annual differences (increase or decrease) between 2012 and
2016 were calculated for DE and NL for the total oral antibiotic drugs
and on the level of antibiotic classes and substances, respectively.TABLE 1 Trends in dispensing of oral antibiotics in Germany and the Ne
Group
DID
2012 2013 2014 2
All systemic antibiotics DE 14.45 15.48 14.16 1
NL 10.36 10.02 9.69
Penicillins DE 4.45 4.85 4.59
NL 4.14 4.08 3.88
Cephalosporins DE 2.68 3.10 2.85
NL 0.03 0.03 0.03
Tetracyclines DE 2.29 2.38 2.03
NL 2.28 2.16 2.06
Quinolones DE 1.43 1.41 1.31
NL 0.75 0.71 0.73
Macrolides DE 1.85 1.98 1.68
NL 1.23 1.13 1.08
Lincosamides DE 0.75 0.75 0.72
DEa 0.50 0.50 0.47
NL 0.15 0.16 0.16
Others DE 1.01 1.01 0.98
NL 1.79 1.75 1.75
aDentists' prescriptions only.
Abbreviations: Avg, average annual change in DID, significant changes in bold
percentage difference between 2016 and 2012 values; NL, the Netherlands.The total annual package numbers of oral antibiotics dispensed
per 1000 inhabitants in DE and in NL were compared within different
age groups. Increase/decrease from 2012 to 2016 was calculated for
each age group in DE and NL.
Furthermore, linear regression analyses were performed to inves-
tigate associations between time (as increasing calendar year) and the
amount of antibiotic dispensings within both countries. For these anal-
yses, a linear relationship was assumed between time and antibiotic
dispensings. The average annual change estimates as well as the corre-
sponding t‐test P‐values were calculated. Statistical analyses were
conducted using IBM SPSS 22. Results with P‐values ≤0.05 were
considered statistically significant.2.5 | Review of national guidelines
We scanned DE and NL guidelines for treatment of RTI, UTI, and
odontogenic infections for their recommendations of oral antibiotic
use. The Clinical Practice Guidelines compiled by the Association of
the Scientific Medical Societies29 (AWMF) were extracted. Informa-
tion for treatment of odontogenic infections was additionally retrieved
from the website of the Federal Chamber of Dentists, the professional
body of all dentists in DE.30 Only current guidelines were included,
those with expired date were not taken into account. In NL, guidelines
for general practitioners are consolidated by the Dutch College of
General Practitioners, Nederlands Huisartsen Genootschap (NHG),
and they were extracted from their website.313 | RESULTS
3.1 | Overall use of antibiotics
Since 2012, the overall consumption of oral antibiotics showed a non‐
significant decrease of −2.2% in DE and −6.9% in NL (Table 1 andtherlands from 2012 to 2016
Δ
Results from Linear Regression
015 2016 Avg P‐value
4.36 14.14 −2.2% −0.176 0.389
9.93 9.64 −6.9% −0.153 0.075
4.75 4.89 9.9% 0.079 0.213
4.04 3.97 −4.0% −0.037 0.286
3.01 2.95 10.2% 0.046 0.448
0.03 0.02 −21.3% −0.002 0.003
1.93 1.88 −17.6% −0.125 0.036
2.09 1.94 −14.9% −0.075 0.018
1.32 1.24 −13.6% −0.048 0.011
0.72 0.69 −7.6% −0.011 0.091
1.71 1.59 −14.4% −0.081 0.088
1.11 1.08 −12.1% −0.031 0.096
0.69 0.67 −10.7% −0.023 0.014
0.44 0.41 −17.8% −0.024 0.006
0.18 0.19 27.5% 0.010 0.001
0.95 0.93 −8.8% −0.024 0.005
1.76 1.75 −2.4% −0.008 0.132
; DE, Germany; DID, defined daily doses per 1000 inhabitants per day; Δ,
GRADL ET AL. 1347Figure 1). In 2016, almost all systemic antibiotics in outpatient care
were dispensed in oral dosage forms (14.14 of 14.18 DID in DE,
9.64 of. 9.69 DID in NL). Overall use of oral antibiotics in DE was
47% higher than in NL (Figure 3).FIGURE 2 Dispensing of oral antibiotics by
age group in Germany and the Netherlands
from 2012 to 2016. DE, Germany; NL, the
Netherlands
FIGURE 1 Dispensing of all oral antibiotics in Germany and the
Netherlands from 2012 to 2016. DE, Germany; DID, defined daily
doses per 1000 inhabitants per day; NL, the Netherlands3.2 | Use of antibiotics in different age groups
During 2012 to 2016, consumption of oral antibiotics by children was
higher in DE compared with NL particularly for the age groups 2 to
5 years (831 vs 408 packages per 1000 inhabitants in 2016) and 6
to 14 years (434 vs 160 packages per 1000 inhabitants in 2016)
(Figure 2). The use decreased significantly in the age groups 0 to 1
and 2 to 5 years in DE (Table 2).3.3 | Use of major classes of antibiotics in 2016
Penicillins were the most frequently used oral antibiotic class in both
countries (4.89 DID in DE, 3.97 in NL) (Table 1). Cephalosporins were
the second most frequently consumed class in DE (2.95 DID), but
hardly used in NL (0.02 DID). A further difference could be observed
in the use of lincosamides with clindamycin as the only representative
of this class (0.67 DID in DE vs 0.19 DID in NL). In addition, in DE,
more oral quinolones (+79%, Figure 3) and macrolides (+47%) were
consumed than in NL. Dispensing of oral tetracyclines was comparable
in both countries (1.88 DID in DE vs 1.94 DID in NL), whereas in NL,
the group of “other antibiotics” was used more frequently than in DE
(1.75 DID in NL vs 0.93 in DE).




Packages per 1000 Inhabitants
Δ
Results from Linear Regression
2012 2013 2014 2015 2016 Avg P‐value
0‐1 DE 480 469 447 420 402 −16.4% −20.638 0.001
NL 425 361 349 363 353 −17.0% −14.299 0.169
2‐5 DE 986 986 898 829 831 −15.8% −46.739 0.015
NL 450 410 389 403 408 −9.4% −9.242 0.243
6‐14 DE 484 507 446 419 434 −10.4% −18.795 0.089
NL 173 163 156 156 160 −8.0% −3.432 0.133
≥15 DE 533 565 520 529 513 −3.7% −7.541 0.290
NL 461 445 433 444 428 −7.1% −6.637 0.082
Abbreviations: Δ, percentage difference between 2016 and 2012 values; Avg, average annual change in packages per 1000 inhabitants, significant changes
in bold; DE, Germany; NL, the Netherlands.
FIGURE 3 Dispensing of oral antibiotics according to different
classes in Germany and the Netherlands in 2016. Percentage
differences as DE − NL. DE, Germany; DID, defined daily doses per
1000 inhabitants per day; NL, the Netherlands
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Between 2012 and 2016, within the major antibiotic classes, only the
use of penicillins and cephalosporins increased (+9.9% /+10.2%) in DE
and lincosamides (clindamycin, +27.5%) in NL, respectively; only the
increase in lincosamide consumption in NL was statistically significant
(P = 0.001). The use of other antibiotic classes decreased significantly
for quinolone antibacterials, lincosamides, tetracyclines, and other
antibiotics in DE compared with cephalosporins and tetracyclines in
NL, respectively. Dentists prescribed 62% of oral clindamycin dis-
pensed in DE in 2016, but clindamycin dispensings based on dentists'
prescriptions decreased significantly (P = 0.006) from 0.50 DID in
2012 to 0.41 in 2016.3.5 | Use of individual antibiotics
Seven of the 10 most frequently used oral antibiotics in 2016 were
in agreement in both countries. Amoxicillin was the most frequently
used oral antibiotic in both countries, followed by cefuroxime and
doxycycline in DE and by doxycycline and amoxicillin with enzyme
inhibitor in NL (Table 3). Three of the 10 most frequently used oral
antibiotics in both countries (ciprofloxacin, azithromycin, and
clarithromycin) belong to the “Watch group antibiotics” according tothe WHO. Oral fosfomycin showed the highest increase from 2012
to 2016 in both countries (87% in DE, 257% in NL, Table 4).3.6 | Overview of guidelines for antibiotic use
Table 5 provides an overview over current DE and NL guidelines for
the treatment of RTI, UTI, and odontogenic infections and lists the
corresponding recommendations for antibiotic use provided.
For acute RTI, the guidelines of both countries advise to be very
reserved in the use of oral antibiotics as they are mainly caused by
viruses. If antibiotics are indicated, penicillins are recommended as
the first choice in most cases. Cephalosporins are not mentioned by
the NL RTI guidelines but listed in DE guidelines for the treatment
of acute exacerbation of chronic obstructive pulmonary disease
(COPD), for rhinosinusitis and as second choice for otitis media acuta
and for pneumonia in patients with risk factors or moderate forms.
Furthermore, cephalosporins are mentioned for certain indications
in case of allergy or intolerance towards penicillins. Fosfomycin and
nitrofurantoin are examples that are recommended in both countries
for the treatment of uncomplicated UTI in women. Guidelines for
odontogenic infections in DE recommend the use of penicillins as a
first choice and erythromycin, clindamycin, or tetracyline as second
choice or in case of penicillin allergy. Experts discourage the systemic
use of antibiotics in NL as well as DE guidelines for peri‐implantation
infections.47,484 | DISCUSSION
4.1 | Overall difference in outpatient use of oral
antibiotics between DE and NL—contextual factors
Oral antibiotic dispensing to outpatients from 2012 to 2016 was
higher in DE compared with NL. Changes during this period were
small. These data are in agreement with consumption of systemic
antibiotics in these countries.1
In NL, a lot of attention is given for cautious use of antibiotics.
General practitioners (GPs) act as gatekeepers in outpatient care and
are educated to a reserved antibiotic prescribing according to
their guidelines.49 This may explain the lower outpatient antibiotic dis-
pensing rates, compared with DE. For example, a study for antibiotic
TABLE 3 Ten most frequently dispensed oral antibiotic substances in Germany and the Netherlands in 2016 (ranking by DID)
Rank (DE) Antibiotic Group DE (DID) NL (DID)
1 Amoxicillin Penicillins 3.45 1.92
2 Cefuroxime Cephalosporins 2.26 0.01
3 Doxycycline Tetracyclines 1.72 1.68
4 Amoxicillin and enzyme inhibitor Penicillins 0.76 1.41
5 Ciprofloxacina Quinolones 0.73 0.56
6 Clindamycin Lincosamides 0.67 0.19
7 Phenoxymethylpenicillin Penicillins 0.55 0.01
8 Azithromycina Macrolides 0.54 0.75
9 Clarithromycina Macrolides 0.54 0.30
10 Nitrofurantoin Others 0.39 1.29
Rank (NL) Antibiotic Group NL (DID) DE (DID)
1 Amoxicillin Penicillins 1.92 3.45
2 Doxycycline Tetracyclines 1.68 1.72
3 Amoxicillin and enzyme inhibitor Penicillins 1.41 0.76
4 Nitrofurantoin Others 1.29 0.39
5 Azithromycina Macrolides 0.75 0.54
6 Ciprofloxacina Quinolones 0.56 0.73
7 Flucloxacillin Penicillins 0.42 0.01
8 Clarithromycina Macrolides 0.30 0.54
9 Sulfamethoxazole and trimethoprim Others 0.26 0.39
10 Minocycline Tetracyclines 0.26 0.14
aWatch group antibiotics (antibiotics according to WHO that have higher resistance potential and so are recommended only for a specific, limited number
of indications as first or second treatment choices32).
Abbreviations: DE, Germany; DID, defined daily doses per 1000 inhabitants per day; NL, the Netherlands.
TABLE 4 Five oral antibiotics with highest growth rates from 2012 to 2016 in Germany and the Netherlands (ranking by DID, only antibiotics




Results from Linear Regression
2012 2013 2014 2015 2016 Avg P‐value
DE
1 Fosfomycin 0.030 0.040 0.046 0.051 0.057 87.5% 0.006 0.001
2 Amoxicillin and enzyme inhibitor 0.537 0.611 0.626 0.697 0.756 40.8% 0.052 0.002
3 Linezolid 0.003 0.003 0.003 0.003 0.004 39.9% 0.000 0.103
4 Flucloxacillin 0.009 0.010 0.011 0.011 0.012 32.8% 0.001 0.009
5 Cefuroxime 1.806 2.194 2.113 2.279 2.257 25.0% 0.099 0.095
NL
1 Fosfomycin 0.012 0.018 0.027 0.035 0.043 256.7% 0.008 0.000
2 Phenoxymethylpenicillin 0.002 0.001 0.001 0.006 0.006 200.1% 0.001 0.097
3 Linezolid 0.001 0.001 0.001 0.001 0.002 30.3% 0.000 0.227
4 Clindamycin 0.148 0.157 0.163 0.177 0.189 27.5% 0.010 0.001
5 Azithromycin 0.633 0.648 0.669 0.740 0.748 18.2% 0.032 0.010
Abbreviations: Avg, average annual change in DID, significant changes in bold; DE, Germany; DID, defined daily doses per 1000 inhabitants per day; Δ,
percentage difference between 2016 and 2012 values; NL, the Netherlands.
GRADL ET AL. 1349prescribing in outpatient care for RTI in 2006/2007 reported a
2.4‐fold higher noncongruent prescribing with European Respiratory
Society guidelines in DE compared with NL.50
In DE, many patients expect an antibiotic when visiting their
GP for a common cold.51 This expectation was associated with a
misperception about how antibiotics should be used, although there
was basic knowledge regarding their action and awareness aboutantibiotic resistance. Frequent prescribing of antibiotics for the treat-
ment of mostly viral conditions, particularly to children, has been
described in DE before.8,52,53 This may explain the higher consump-
tion of antibiotics in children in DE. Due to the lack of additional
information on patient level, we could not analyze the role of con-
textual factors in the differences in antibiotic prescribing between
DE and NL.
TABLE 5 Recommendations for oral antibiotics use in national guidelines
Guideline Indication Antibiotic Substance Comment
DE
Upper respiratory tract infections
S2k† guideline “Rhinosinusitis”, 2017,
AWMF‐Reg.‐no. 017‐049, 053‐012,
DGHNO‐KHCa), DEGAMb) 33
Acute rhinosinusitis First choice: Amoxicillin or
cephalosporins (cefuroxime)
Second choice: Macrolides,
amoxicillin and enzyme inhibitor,
doxycycline or co‐trimoxazole
Generally no antibiotic
Consider only for patients with specific









Clarithromycin, doxycycline Consider for cases when standard
therapy fails
S2k guideline “Earache”, 2014,
AWMF‐Reg.‐no. 053‐009,
DEGAMb) 34
Otitis media acuta First choice: Amoxicillin (if necessary
with enzyme inhibitor)
Second choice: second generation
cephalosporin
If allergic to penicillins or
cephalosporins: Macrolides
Immediate antibiotic therapy only in
patients with high risk (eg, children
<6 months of age, children 6‐23
months of age with bilateral otitis,
patients with ventilation tubes,
otorrhea, immunosuppression;
persistent vomiting)
For all others: Generally no immediate
antibiotic therapy





Depends on antibiogram For cases when standard therapy (local
antiseptic/antibiotic) fails
S2k guideline “Treatment of
inflammatory diseases of the






In case of intolerance towards
penicillins: Erythromycin estolate,
first generation cephalosporins
Consider only for patients with
confirmed or strongly suspected
streptococcal tonsillitis
Lower respiratory tract infections





Antibiotics are not recommended
Consider only for patients with severe
cardiac or respiratory diseases,
immunodeficiencies, or elderly
patients, eg, in case of pneumonia
(see below)










S3 guideline “Cough”, 2014,
AWMF‐Reg.‐no. 053‐013, DEGAMb)
Pneumonia For patients without risk factors:
Aminopenicillins, tetracyclines, or
macrolides
For patients with risk factors: First
choice: Aminopenicillins and
enzyme inhibitor, second choice:
second generation cephalosporins
Risk factors include, eg, antibiotic
therapy within the past 3 months,
residents of nursery homes, COPD,
diabetes mellitus due to extended
spectrum of pathogens
S3 guideline “Cough”, 2014,
AWMF‐Reg.‐no. 053‐013, DEGAMb)
Pertussis Azithromycin, clarithromycin





Pneumonia Mild form without comorbidities:
Aminopenicillins






Mild form with comorbidities:
Aminopenicillins and enzyme
inhibitor
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TABLE 5 (Continued)
Guideline Indication Antibiotic Substance Comment
S2k guideline “Management of
community‐acquired pneumonia in
children and adolescents”, 2017,
AWMF‐Reg.‐no. 048‐013, DGPIf),
GPPg) 38




(≥ 9 years of age)
In case of complications or treatment
failure: Aminopenicillins and
enzyme inhibitor or second
generation cephalosporins
Not every patient has to be treated
with an antibiotic
Odontogenic infections
Information on dental medication,
2017, BZÄKh), KZBVi) 39
Bacterial infections For gram (+) pathogens
First choice: Oral penicillins
Second choice: Erythromycin,
clindamycin
For mixed infections with gram(−)
pathogens
First choice amoxicillin (and enzyme
inhibitor)
In case of penicillin allergy
Tetracyclines
No routine application, restricted
indication
only!






In case of penicillin allergy:
Clindamycin, cephalosporins,
macrolides
In specific patient groups with high risk




Only in severe cases or when standard
therapy fails in specific patient groups







In case of penicillin allergy:
Clindamycin
Only in case of infiltrates or local
infections in patients with risk factors
or if the infection tends to spread
Urinary tract infections
S3 guideline “Epidemiology, diagnostics,
therapy, prevention, and management
of uncomplicated bacterial





For pre‐ and postmenopausal women
fosfomycin, nitrofurantoin,
nitroxolin, or pivmecillinam
For men (if prostate is not involved)
pivmecillinam or nitrofurantoin
Choice of antibiotic depends on
individual risk, pathogen spectrum,




NOT be used as first choice
S3 guideline “Epidemiology, diagnostics,
therapy, prevention and management
of uncomplicated bacterial
community acquired urinary tract
infections”, 2017, AWMF‐Reg.‐no.
043‐044, DGUl)
Pyelonephritis For pre‐ and postmenopausal women
and moderate cases ciprofloxacin,
levofloxacin, cefpodoxim, ceftibuten
For men fluorochinolones
S3 guideline “Epidemiology, diagnostics,
therapy, prevention and management
of uncomplicated bacterial
community acquired urinary tract
infections”, 2017, AWMF‐Reg.‐no.
043‐044, DGUl)




cefalexin, ofloxacin only if other
substances can NOT be used.
NL




For penicillin allergy doxycycline or,
when doxycycline is
contraindicated (pregnancy,
children <8 years) co‐trimoxazol
For severe cases




Alternatively amoxicillin + enzyme
inhibitor
For penicillin allergy azithromycin




Guideline “Otitis media acuta bij
kinderen” (NHGm)), 2015, M0944
Otitis media acuta Amoxicillin
(Continues)
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TABLE 5 (Continued)
Guideline Indication Antibiotic Substance Comment
In case of contra‐indications for
amoxicillin:
Co‐trimoxazol
If amoxicillin shows no effect:
Amoxicillin and enzyme inhibitor
Lower respiratory tract infections



















Guideline “Urineweginfecties” (NHGm)), 2013,
M0546





amoxicillin, and enzyme inhibitor
Complicated cases: Amoxicillin and
enzyme inhibitor, co‐trimoxazol
†S2k guidelines are a formal consent of an expert group.29
‡S3 guidelines include all elements of a systematic development (logic, decision, and outcome analysis).29
a)German Society of Oto‐Rhino‐Laryngology, Head and Neck Surgery.
b)German College of General Practitioners and Family Physicians.
c)The German Respiratory Society.
d)German Society of Infectious Diseases.
e)Paul‐Ehrlich Society of Chemotherapy.
f)German Society for Pediatric Infectious Diseases.
g)The Society for Pediatric Pneumology.
h)Bundeszahnärztekammer—Arbeitsgemeinschaft der Deutschen Zahnärztekammern (BZÄK), the professional body of all dentists in Germany.
i)National Association of Statutory Health Insurance Dentists.
j)The German Society for Oral and Maxillofacial Surgery.
k)German Society of Dentistry and Oral Medicine.
l)German Society of Urology.
m)Nederlands Huisartsen Genootschap (NHG).
Abbreviations: DE, Germany; NL, the Netherlands.
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individual substances based on medical evidence
Guidelines are based on medical evidence and, assuming a similar
prevalence of indications, can reveal reasons for differences in pre-
scribing behaviour between countries.33-48 The most frequent indica-
tions for antibiotic prescriptions to children in DE are otitis media,
tonsillitis, other upper RTI and bronchitis.8,52 These indications are
responsible for between 70% and 80% of all antibiotic prescriptions
to children younger than 15 years. DE and NL RTI guidelines do not
differ substantially with respect to their first choices of oral antibiotics.
There are also no large differences with respect to restrictive use of
clindamycin, chinolones, and cephalosporins.
We have no evidence for differences in infection prevalence
in both countries (eg, respiratory diseases54) which would justify
the huge discrepancies in, for example, use of cefuroxime or
clindamycin between NL and DE. The use of oral cefuroxime is only
justified for pathogens (except for UTI) with a minimum inhibitoryconcentration well below 1 μg/mL, which is the case for, eg,
Streptococcus pneumoniae. Many other pathogens require much
higher concentrations of cefuroxime which cannot be reached with
approved oral products.55 The high consumption for oral cephalo-
sporins in outpatients in DE corresponds with earlier findings for
all cephalosporins and suggests overuse.56
Due to actual resistance patterns and more side effects compared
with penicillins, in German guidelines for dental diseases, clindamycin
is only recommended in case of penicillin allergy or as second choice
treatment.39 This recommendation does not match with the high dis-
pensing rates for prescriptions by dentists. Overprescription of
clindamycin by German dentists has been described before.57,58 Our
data suggest, however, that guideline adherence by dentists may have
improved over the past years.
According to the summary of product characteristics, fosfomycin
is primarily prescribed for UTI in women. Although we could not
analyze fosfomycin use by gender, the fact that the use of oral
fosfomycin remarkedly increased in both countries let us assume it is
GRADL ET AL. 1353increasingly used for this indication. For UTI in women, it can replace
fluoroquinolones, cephalosporins, and co‐trimoxazol, in line with
guidelines for treatment of uncomplicated UTI (guideline in NL since
2013).59,60 The latter are associated with a higher risk of side effects
and a selection of multiresistant pathogens.59,614.3 | Strengths and limitations
The strength of employing pharmacy claims‐based databases for drug
utilization studies is the access to a very large study population. Both
databases dispose of information on dispensings to the majority of the
population in DE and NL. It should be noted that the study was limited
to the population insured by the SHI system in DE and that dispens-
ings of antibiotics to privately insured patients were not included. This
might have introduced a bias in the comparison with NL. However,
this is not expected to be substantial. Another particular strength of
the DAPI and the SFK databases is actuality of their data enabling us
to cover the most recent period.
A major shortcoming of our study is that individual patient data
such as prescribed doses for DE and information on diagnosis for both
countries were lacking and comparison of antibiotic use was limited to
overall dispensing data. Differences in consumption between both
countries may thus originate in differences in absolute patient num-
bers treated per 1000 in the total population as well as in differences
in dose or therapy duration of the antibiotics. We have noted that rec-
ommendations for antibiotic use in Dutch guidelines for treatment of
RTI were more conservative with respect to dose in some cases, eg,
for otitis media and amoxicillin,34,44 but without individual patient data
the extent of such effects is merely speculative. A further limitation is
that analyses of age groups were hampered by a potential underesti-
mation of the group 0 to 1 years of age since exact date of birth
was not available. However, since in both countries the algorithm for
assigning the year of age to a prescription was similar, the extent of
underestimation is comparable in both countries. Dispensing data,
finally, are only a surrogate for drug use because how many units of
the packages dispensed are actually taken is unknown.5 | CONCLUSION
A comparison of outpatient antibiotic use between DE and NL shows
that from 2012 to 2016 in NL this use was much lower than in DE
(9.64 DID vs 14.14 DID in 2016). Differences were primarily observed
in the age groups 2 to 5 (2.0‐fold in 2016) and 6 to 14 years (2.7‐fold
in 2016). A further remarkable difference could be identified in the
amount of cephalosporins dispensed. There was almost no use in NL
(0.02 DID in 2016), but cephalosporins were the second most utilized
class in DE (2.95 DID in 2016). In both countries, fosfomycin had the
highest growth rate by DID from 2012 to 2016.
National guidelines for most common infections in DE and NL
were comparable for their recommendations in antibiotic use. Conse-
quently, this could not account for the higher antibiotic use in DE
compared with NL. Obviously, in NL the guidelines have to be better
implemented than in DE for appropriate antibiotic prescribing. Further
research is needed on how to improve antibiotic use in DE and learnfrom NL. In addition, this might address details on infection incidences
and diagnoses as well as GP education and patient information for a
more restrictive antibiotic use. Pharmacists might play a role in this
as well by monitoring GP prescribing and counseling patients. In NL,
pharmacists confront GPs in regular pharmacotherapy audit circles
with their prescription data for different diseases and drug classes.
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